Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies

Kevin H. Chen, Masayuki Wada, Amelia E. Firor, Kevin G. Pinz, Alexander Jares, Hua Liu, Huda Shafic Salman, Marc Golightly, Fengshuo Lan, Xun Jiang, Yupo Ma

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Peripheral T-cell lymphomas (PTCLS) comprise a diverse group of difficult to treat, very aggressive non-Hodgkin's lymphomas (NHLS) with poor prognoses and dismal patient outlook. Despite the fact that PTCLs comprise the majority of T-cell malignancies, the standard of care is poorly established. Chimeric antigen receptor (CAR) immunotherapy has shown in B-cell malignancies to be an effective curative option and this extends promise into treating T-cell malignancies. Because PTCLS frequently develop from mature T-cells, CD3 is similarly strongly and uniformly expressed in many PTCL malignancies, with expression specific to the hematological compartment thus making it an attractive target for CAR design. We engineered a robust 3rd generation anti-CD3 CAR construct (CD3CAR) into an NK cell line (NK-92). We found that CD3CAR NK-92 cells specifically and potently lysed diverse CD3+ human PTCL primary samples as well as T-cell leukemia cells lines ex vivo. Furthermore, CD3CAR NK-92 cells effectively controlled and suppressed Jurkat tumor cell growth in vivo and significantly prolonged survival. In this study, we present the CAR directed targeting of a novel target - CD3 using CAR modified NK-92 cells with an emphasis on efficacy, specificity, and potential for new therapeutic approaches that could improve the current standard of care for PTCLs.

Original languageEnglish (US)
Pages (from-to)56219-56232
Number of pages14
JournalOncotarget
Volume7
Issue number35
DOIs
StatePublished - Jan 1 2016

Fingerprint

CD3 Antigens
Antigen Receptors
Natural Killer Cells
T-Lymphocytes
Peripheral T-Cell Lymphoma
Neoplasms
Standard of Care
T-Cell Leukemia
Cell Line
Jurkat Cells
Non-Hodgkin's Lymphoma
Immunotherapy
B-Lymphocytes
Survival
Growth

Keywords

  • CD3CAR
  • Immunotherapy
  • NK cells
  • T cell malignancies

ASJC Scopus subject areas

  • Oncology

Cite this

Chen, K. H., Wada, M., Firor, A. E., Pinz, K. G., Jares, A., Liu, H., ... Ma, Y. (2016). Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget, 7(35), 56219-56232. https://doi.org/10.18632/oncotarget.11019

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. / Chen, Kevin H.; Wada, Masayuki; Firor, Amelia E.; Pinz, Kevin G.; Jares, Alexander; Liu, Hua; Salman, Huda Shafic; Golightly, Marc; Lan, Fengshuo; Jiang, Xun; Ma, Yupo.

In: Oncotarget, Vol. 7, No. 35, 01.01.2016, p. 56219-56232.

Research output: Contribution to journalArticle

Chen, KH, Wada, M, Firor, AE, Pinz, KG, Jares, A, Liu, H, Salman, HS, Golightly, M, Lan, F, Jiang, X & Ma, Y 2016, 'Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies', Oncotarget, vol. 7, no. 35, pp. 56219-56232. https://doi.org/10.18632/oncotarget.11019
Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget. 2016 Jan 1;7(35):56219-56232. https://doi.org/10.18632/oncotarget.11019
Chen, Kevin H. ; Wada, Masayuki ; Firor, Amelia E. ; Pinz, Kevin G. ; Jares, Alexander ; Liu, Hua ; Salman, Huda Shafic ; Golightly, Marc ; Lan, Fengshuo ; Jiang, Xun ; Ma, Yupo. / Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. In: Oncotarget. 2016 ; Vol. 7, No. 35. pp. 56219-56232.
@article{5727b2e8ab6b470aafd34e9896861d6f,
title = "Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies",
abstract = "Peripheral T-cell lymphomas (PTCLS) comprise a diverse group of difficult to treat, very aggressive non-Hodgkin's lymphomas (NHLS) with poor prognoses and dismal patient outlook. Despite the fact that PTCLs comprise the majority of T-cell malignancies, the standard of care is poorly established. Chimeric antigen receptor (CAR) immunotherapy has shown in B-cell malignancies to be an effective curative option and this extends promise into treating T-cell malignancies. Because PTCLS frequently develop from mature T-cells, CD3 is similarly strongly and uniformly expressed in many PTCL malignancies, with expression specific to the hematological compartment thus making it an attractive target for CAR design. We engineered a robust 3rd generation anti-CD3 CAR construct (CD3CAR) into an NK cell line (NK-92). We found that CD3CAR NK-92 cells specifically and potently lysed diverse CD3+ human PTCL primary samples as well as T-cell leukemia cells lines ex vivo. Furthermore, CD3CAR NK-92 cells effectively controlled and suppressed Jurkat tumor cell growth in vivo and significantly prolonged survival. In this study, we present the CAR directed targeting of a novel target - CD3 using CAR modified NK-92 cells with an emphasis on efficacy, specificity, and potential for new therapeutic approaches that could improve the current standard of care for PTCLs.",
keywords = "CD3CAR, Immunotherapy, NK cells, T cell malignancies",
author = "Chen, {Kevin H.} and Masayuki Wada and Firor, {Amelia E.} and Pinz, {Kevin G.} and Alexander Jares and Hua Liu and Salman, {Huda Shafic} and Marc Golightly and Fengshuo Lan and Xun Jiang and Yupo Ma",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.11019",
language = "English (US)",
volume = "7",
pages = "56219--56232",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "35",

}

TY - JOUR

T1 - Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies

AU - Chen, Kevin H.

AU - Wada, Masayuki

AU - Firor, Amelia E.

AU - Pinz, Kevin G.

AU - Jares, Alexander

AU - Liu, Hua

AU - Salman, Huda Shafic

AU - Golightly, Marc

AU - Lan, Fengshuo

AU - Jiang, Xun

AU - Ma, Yupo

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Peripheral T-cell lymphomas (PTCLS) comprise a diverse group of difficult to treat, very aggressive non-Hodgkin's lymphomas (NHLS) with poor prognoses and dismal patient outlook. Despite the fact that PTCLs comprise the majority of T-cell malignancies, the standard of care is poorly established. Chimeric antigen receptor (CAR) immunotherapy has shown in B-cell malignancies to be an effective curative option and this extends promise into treating T-cell malignancies. Because PTCLS frequently develop from mature T-cells, CD3 is similarly strongly and uniformly expressed in many PTCL malignancies, with expression specific to the hematological compartment thus making it an attractive target for CAR design. We engineered a robust 3rd generation anti-CD3 CAR construct (CD3CAR) into an NK cell line (NK-92). We found that CD3CAR NK-92 cells specifically and potently lysed diverse CD3+ human PTCL primary samples as well as T-cell leukemia cells lines ex vivo. Furthermore, CD3CAR NK-92 cells effectively controlled and suppressed Jurkat tumor cell growth in vivo and significantly prolonged survival. In this study, we present the CAR directed targeting of a novel target - CD3 using CAR modified NK-92 cells with an emphasis on efficacy, specificity, and potential for new therapeutic approaches that could improve the current standard of care for PTCLs.

AB - Peripheral T-cell lymphomas (PTCLS) comprise a diverse group of difficult to treat, very aggressive non-Hodgkin's lymphomas (NHLS) with poor prognoses and dismal patient outlook. Despite the fact that PTCLs comprise the majority of T-cell malignancies, the standard of care is poorly established. Chimeric antigen receptor (CAR) immunotherapy has shown in B-cell malignancies to be an effective curative option and this extends promise into treating T-cell malignancies. Because PTCLS frequently develop from mature T-cells, CD3 is similarly strongly and uniformly expressed in many PTCL malignancies, with expression specific to the hematological compartment thus making it an attractive target for CAR design. We engineered a robust 3rd generation anti-CD3 CAR construct (CD3CAR) into an NK cell line (NK-92). We found that CD3CAR NK-92 cells specifically and potently lysed diverse CD3+ human PTCL primary samples as well as T-cell leukemia cells lines ex vivo. Furthermore, CD3CAR NK-92 cells effectively controlled and suppressed Jurkat tumor cell growth in vivo and significantly prolonged survival. In this study, we present the CAR directed targeting of a novel target - CD3 using CAR modified NK-92 cells with an emphasis on efficacy, specificity, and potential for new therapeutic approaches that could improve the current standard of care for PTCLs.

KW - CD3CAR

KW - Immunotherapy

KW - NK cells

KW - T cell malignancies

UR - http://www.scopus.com/inward/record.url?scp=84984919508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984919508&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11019

DO - 10.18632/oncotarget.11019

M3 - Article

VL - 7

SP - 56219

EP - 56232

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 35

ER -